Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Daniel StopperDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.ORCID 0009-0009-0610-7830
Lukas BiermannInstitute of Pharmaceutical and Medicinal Chemistry, University of Düsseldorf, 40225 Düsseldorf, Germany.
Paris R WatsonRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.
Jingyu LiInstitute of Pharmaceutical and Medicinal Chemistry, University of Düsseldorf, 40225 Düsseldorf, Germany.
Beate KönigDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
Matthew N GaynesRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.ORCID 0000-0001-9649-601X
Lais Pessanha de CarvalhoInstitute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.ORCID 0000-0002-3857-5462
Jana KloseDepartment of Applied Biosciences and Process Technology, Anhalt University of Applied Sciences, 06366 Köthen, Germany.
Maria HanlDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
Alexandra HamacherInstitute of Pharmaceutical and Medicinal Chemistry, University of Düsseldorf, 40225 Düsseldorf, Germany.
Linda Schäker-HübnerDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
Daniel RamsbeckDepartment of Applied Biosciences and Process Technology, Anhalt University of Applied Sciences, 06366 Köthen, Germany.ORCID 0000-0002-4966-142X
Jana HeldInstitute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.ORCID 0000-0002-7970-1429
David W ChristiansonRoy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.ORCID 0000-0002-0194-5212
Matthias U KassackInstitute of Pharmaceutical and Medicinal Chemistry, University of Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0002-9094-8481
Finn K HansenDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.ORCID 0000-0001-9765-5975
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI STEVEN E EALICK · 2018 to 2026
$34.2M
Structure and Function of MetalloenzymesR01GM049758 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIANSON, DAVID W · 1994 to 2025
$7.6M
Predoctoral Training at the Chemistry-Biology InterfaceT32GM133398 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ronen Marmorstein, Ernest James Petersson · 2020 to 2026
In this work, we synthesized a series of peptoid-based histone deacetylase (HDAC) inhibitors with variations in the linker region and zinc-binding groups. All compounds were investigated for their HDAC inhibition, antiplasmodial activity, and cytotoxicity against native and cisplatin-resistant carcinoma cell lines. The ethylhydrazide
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers · full record | OpenQuestion